The U.S. could save roughly $50 billion each year on biologics by opting for price-setting methods post-exclusivity, according to a FiercePharma report, which is “up to 10 times” the savings from biosimilars.
Biosimilars, per the report, are not only difficult to manufacture, but their performance in the market is not a sure thing.
The authors of a recent article in Health Affairs suggested that price regulations could prove more effective than increased competition at delivering significant savings.
FiercePharma reports the authors told it that an “independent body, not the government” should be responsible for setting prices post-exclusivity.
To read the full report on FiercePharma, click here.